Dhanvantri Jeev. (531043)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at ₹19.95 versus book value of ₹24.75, a 0.81x P/B discount to net assets.
• Sales grew 27.54%, indicating business expansion in healthcare services.
• Piotroski F-score of 7/9 suggests a reasonably sound financial position.
• Small market cap of ₹8 Cr and book value provide a potential asset cushion for patient investors.

Concerns

• ROE of 1.87% and ROCE of 5.82% reflect poor capital productivity.
• Latest quarter net profit is effectively zero despite ₹7 Cr sales.
• P/E of 83.67 and PEG of 4.09 make the earnings valuation unattractive.
• No dividend, no promoter holding data, and near 52-week low add uncertainty.

AI Analysis

At ₹19.95, Dhanvantri Jeev is a microcap healthcare services company with a market capitalization of just ₹8 crore. The first thing that catches my eye is the balance sheet: book value is ₹24.75, so the stock trades at only 0.81 times book. Benjamin Graham taught us to look for a margin of safety, and on assets alone, this seems to offer one. But I have to ask whether those assets are productive. The numbers say no—ROE is a weak 1.87% and ROCE is just 5.82%. The latest quarter shows sales of ₹7 crore but net profit of essentially zero, so the business is not generating meaningful earnings today. Sales growth of 27.54% is encouraging, but profit growth of only 13.33% tells me that expansion is not translating into improving margins. At a P/E of 83.67, the market is paying a very high multiple for very small profits, and the PEG ratio of 4.09 confirms that the growth is not inexpensive. There is no dividend, so the return here can only come from asset re-rating or a genuine improvement in earnings. The Piotroski F-score of 7/9 suggests the company's fundamentals are not deteriorating badly, which is a small positive. However, without promoter holding data or a clear debt-equity picture, I am working with an incomplete picture. This is not a wonderful business by my standards. A wonderful business earns high returns on capital and throws off cash; this one has an asset cushion and some sales momentum, but it has not proven it can generate solid shareholder returns. I would classify this as an asset play, not a compounder. I need to see higher ROE, positive net profits, and better disclosure before I would consider owning it. The discount to book is interesting, but not sufficient.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer